Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the second quarter 2025 Total revenue increased 13 per cent, 22 per cent at constant exchange rates, (CER) 1, to SEK 6,175 M ...

ADC Therapeutics' CD19-directed ADC ZYNLONTA (loncastuximab tesirine-lpyl) received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of ...

ZYNLONTA was generally well tolerated, with safety findings consistent with its existing clinical profile.

ZYNLONTA was generally well tolerated, with safety findings consistent with its existing clinical profile.

Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the second quarter 2025 Second Quarter 2025 Total ...